X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of Ruvidar (TLD-1433), a novel photosensitizer, currently being evaluated in a phase II clinical trial for treating high-risk non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TSX Venture Exchange
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 05, 2024
Details:
TLD-1433 (ruvidar) is a ruthenium-based photodynamic compound. It is under phase 2 clinical development for the treatment of patients with non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 29, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 17, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Financing October 23, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Ruvidar (TLD-1433), is an exciting new drug candidate for the treatment for NMIBC and has been proven to be safe and effective in a phase Ib clinical study in the safe and effective treatment of NMIBC.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The Company intends to use the proceeds for the advancement of Phase II non-muscle invasive bladder cancer clinical study evaluating TLD 1433, a ruthenium metal-based molecule.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 30, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
TLD-1433 is a patented PDC with 12 years of published peer reviewed preclinical research and is currently under investigation in Study II. Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm2) activated by the proprietary TLC-3200 medical laser system.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
